by Sermonix Pharmaceuticals | May 28, 2019 | News
Designation allows for expedited development and review of lasofoxifene as a potential precision medicine treatment for women who have estrogen receptor-positive (ER+) metastatic breast cancer with an ESR1 mutation COLUMBUS, Ohio, May 28, 2019 (GLOBE NEWSWIRE) —...
by Sermonix Pharmaceuticals | May 7, 2019 | News
Biopharmaceutical company studied combination of lasofoxifene and CDK4/6 inhibitor palbociclib versus fulvestrant and palbociclib in animal models. COLUMBUS, Ohio (May 7, 2019) – Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the...
Recent Comments